Persistent C. pneumoniae infection in atherosclerotic lesions: Rethinking the clinical trials

Frontiers in Cellular and Infection Microbiology

Volumn 5, Issue MAR, 2014, Pages

  Campbell, Lee Ann ^a   Rosenfeld, Michael E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Antibiotics; Atherosclerosis; Chlamydia pneumoniae; Clinical trials; Persistence

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; CLARITHROMYCIN; GATIFLOXACIN; RIFALAZIL; ROXITHROMYCIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; ARTICLE; ATHEROSCLEROSIS; CHLAMYDIAL PNEUMONIA; CLINICAL TRIAL (TOPIC); HEART TRANSPLANTATION; HUMAN; IMMUNOHISTOCHEMISTRY; ISCHEMIC HEART DISEASE; NONHUMAN; PERSISTENT INFECTION; POLYMERASE CHAIN REACTION; RESPIRATORY TRACT INFECTION; RISK FACTOR; SEROEPIDEMIOLOGY; TISSUE MICROARRAY; TRANSMISSION ELECTRON MICROSCOPY; ANIMAL; CHLAMYDOPHILA INFECTION; CHLAMYDOPHILA PNEUMONIAE; DISEASE MODEL; ISOLATION AND PURIFICATION; PATHOLOGY; PERSISTENCE; PHYSIOLOGY; REVIEW; TREATMENT FAILURE;

ANTIBIOTICS; ATHEROSCLEROSIS; CHLAMYDIA PNEUMONIAE; CLINICAL TRIALS; PERSISTENCE;

ANIMALS; ANTI-BACTERIAL AGENTS; ATHEROSCLEROSIS; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; TREATMENT FAILURE;

EID: 84898034935     PISSN: None     EISSN: 22352988     Source Type: Journal    
DOI: 10.3389/fcimb.2014.00034     Document Type: Article

References (42)

1. Anderson, J. L. (2005). Infection, antibiotics, and atherothrombosis-end of the road or new beginnings? N. Engl. J. Med. 352, 1706-1709. doi: 10.1056/NEJMe058019
2. Beatty, W. L., Morrison, R. P., and Byrne, G. I. (1994). Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis. Microbiol. Rev. 58, 686-699.
3. Blessing, E., Campbell, L. A., Rosenfeld, M. E., Chesebro, B., and Kuo, C. C. (2005). A 6 week course of azithromycin treatment has no beneficial effect on atherosclerotic lesion development in apolipoprotein E-deficient mice chronically infected with Chlamydia pneumoniae. J. Antimicrob. Chemother. 55, 1037-1040. doi: 10.1093/jac/dki128
4. Blessing, E., Campbell, L. A., Rosenfeld, M. E., Chough, N., and Kuo, C. C. (2001). Chlamydia pneumoniae infection accelerates hyperlipidemia induced atherosclerotic lesion development in C57BL/6J mice. Atherosclerosis 158, 13-17. doi: 10.1016/S0021-9150(00)00758-9
5. Borel, N., Mukhopadhyay, S., Kaiser, C., Sullivan, E. D., Miller, R. D., Timms, P., et al. (2006). Tissue MicroArray (TMA) analysis of normal and persistent Chlamydophila pneumoniae infection. BMC Infect. Dis. 6:152. doi: 10.1186/1471-2334-6-152
6. Borel, N., Pospischil, A., Dowling, R. D., Dumrese, C., Gaydos, C. A., Bunk, S., et al. (2012). Antigens of persistent Chlamydia pneumoniae within coronary atheroma from patients undergoing heart transplantation. J. Clin. Pathol. 65, 171-177. doi: 10.1136/jclinpath-2011-200270
7. Borel, N., Summersgill, J. T., Mukhopadhyay, S., Miller, R. D., Ramirez, J. A., and Pospischil, A. (2008). Evidence for persistent Chlamydia pneumoniae infection of human coronary atheromas. Atherosclerosis 199, 154-161. doi: 10.1016/j.atherosclerosis.2007.09.026
8. Campbell, L. A., and Kuo, C. C. (2004). Chlamydia pneumoniae-an infectious risk factor for atherosclerosis? Nat. Rev. Microbiol. 2, 23-32. doi: 10.1038/nrmicro796
9. Cannon, C. P., Braunwald, E., McCabe, C. H., Grayston, J. T., Muhlestein, B., Giugliano, R. P., et al. (2005). Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N. Engl. J. Med. 352, 1646-1654. doi: 10.1056/NEJMoa043528
10. Carey, A. J., Huston, W. M., Cunningham, K. A., Hafner, L. M., Timms, P., and Beagley, K. W. (2013). Characterization of in vitro Chlamydia muridarum persistence and utilization in an in vivo mouse model of Chlamydia vaccine. Am. J. Reprod. Immunol. 69, 475-485. doi: 10.1111/aji.12093
11. Carter, J. D., Espinoza, L. R., Inman, R. D., and Hudson, A. P. (2010). Combination antibiotics as a treatment for chronic Chlamydia-induced reactive arthritis: a double-blind, placebo-controlled, prospective trial. Arthritis Rheum. 62, 1298-1307. doi: 10.1002/art.27394
12. Danesh, J. (2005). Antibiotics in the prevention of heart attacks. Lancet 365, 365-367. doi: 10.1016/S0140-6736(05)17842-8
13. Deniset, J. F., and Pierce, G. N. (2010). Possibilities for therapeutic interventions in disrupting Chlamydophila pneumoniae involvement in atherosclerosis. Fundam. Clin. Pharmacol. 24, 607-617. doi: 10.1111/j.1472-8206.2010.00863.x
14. Epstein, S. E., Zhu, J., Najafi, A. H., and Burnett, M. S. (2009). Insights into the role of infection in atherogenesis and in plaque rupture. Circulation 119, 3133-3141. doi: 10.1161/CIRCULATIONAHA.109.849455
15. Fong, I. W. (2000). Antibiotics effects in a rabbit model of Chlamydia pneumoniae-induced atherosclerosis. J. Infect. Dis. 181(Suppl. 3), S514-S518. doi: 10.1086/315607
16. Gieffers, J., Fullgraf, H., Jahn, J., Klinger, M., Dalhoff, K., Katus, H. A., et al. (2001). Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation 103, 351-356. doi: 10.1161/01.CIR.103.3.351
17. Gieffers, J., Rupp, J., Gebert, A., Solbach, W., and Klinger, M. (2004). First-choice antibiotics at subinhibitory concentrations induce persistence of Chlamydia pneumoniae. Antimicrob. Agents Chemother. 48, 1402-1405. doi: 10.1128/AAC.48.4.1402-1405.2004
18. Grayston, J. T. (2003). Antibiotic treatment of atherosclerotic cardiovascular disease. Circulation 107, 1228-1230. doi: 10.1161/01.CIR.0000056032.56396.89
19. Grayston, J. T., Kronmal, R. A., Jackson, L. A., Parisi, A. F., Muhlestein, J. B., Cohen, J. D., et al. (2005). Azithromycin for the secondary prevention of coronary events. N. Engl. J. Med. 352, 1637-1645. doi: 10.1056/NEJMoa043526
20. Hu, H., Pierce, G. N., and Zhong, G. (1999). The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae. J. Clin. Invest. 103, 747-753. doi: 10.1172/JCI4582
21. Jackson, L. A., Campbell, L. A., Kuo, C. C., Rodriguez, D. I., Lee, A., and Grayston, J. T. (1997). Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen. J. Infect. Dis. 176, 292-295. doi: 10.1086/517270
22. Jaff, M. R., Dale, R. A., Creager, M. A., Lipicky, R. J., Constant, J., Campbell, L. A., et al. (2009). Anti-chlamydial antibiotic therapy for symptom improvement in peripheral artery disease: prospective evaluation of rifalazil effect on vascular symptoms of intermittent claudication and other endpoints in Chlamydia pneumoniae seropositive patients (PROVIDENCE-1). Circulation 119, 452-458. doi: 10.1161/CIRCULATIONAHA.108.815308
23. Jespersen, C. M., Als-Nielsen, B., Damgaard, M., Hansen, J. F., Hansen, S., Helo, O. H., et al. (2006). Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial. BMJ 332, 22-27. doi: 10.1136/bmj.38666.653600.55
24. Joensen, J. B., Juul, S., Henneberg, E., Thomsen, G., Ostergaard, L., and Lindholt, J. S. (2008). Can long-term antibiotic treatment prevent progression of peripheral arterial occlusive disease? A large, randomized, double-blinded, placebo-controlled trial. Atherosclerosis 196, 937-942. doi: 10.1016/j.atherosclerosis.2007.02.025
25. Kutlin, A., Roblin, P. M., and Hammerschlag, M. R. (2002a). Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous-infection Model. Antimicrob. Agents Chemother. 46, 409-412. doi: 10.1128/AAC.46.2.409-412.2002
26. Kutlin, A., Roblin, P. M., and Hammerschlag, M. R. (2002b). Effect of gemifloxacin on viability of Chlamydia pneumoniae (Chlamydophila pneumoniae) in an in vitro continuous infection model. J. Antimicrob. Chemother. 49, 763-767. doi: 10.1093/jac/dkf029
27. Laitinen, K., Laurila, A. L., Leinonen, M., and Saikku, P. (1996). Reactivation of Chlamydia pneumoniae infection in mice by cortisone treatment. Infect. Immun. 64, 1488-1490.
28. Malinverni, R., Kuo, C. C., Campbell, L. A., and Grayston, J. T. (1995a). Reactivation of Chlamydia pneumoniae lung infection in mice by cortisone. J. Infect. Dis. 172, 593-594. doi: 10.1093/infdis/172.2.593
29. Malinverni, R., Kuo, C. C., Campbell, L. A., Lee, A., and Grayston, J. T. (1995b). Effects of two antibiotic regimens on course and persistence of experimental Chlamydia pneumoniae TWAR pneumonitis. Antimicrob. Agents Chemother. 39, 45-49. doi: 10.1128/AAC.39.1.45
30. Moazed, T. C., Campbell, L. A., Rosenfeld, M. E., Grayston, J. T., and Kuo, C. C. (1999). Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. J. Infect. Dis. 180, 238-241. doi: 10.1086/314855
31. Moazed, T. C., Kuo, C., Grayston, J. T., and Campbell, L. A. (1997). Murine models of Chlamydia pneumoniae infection and atherosclerosis. J. Infect. Dis. 175, 883-890. doi: 10.1086/513986
32. Molestina, R. E., Klein, J. B., Miller, R. D., Pierce, W. H., Ramirez, J. A., and Summersgill, J. T. (2002). Proteomic analysis of differentially expressed Chlamydia pneumoniae genes during persistent infection of HEp-2 cells. Infect. Immun. 70, 2976-2981. doi: 10.1128/IAI.70.6.2976-2981.2002
33. Muhlestein, J. B. (2011). Chronic infection and coronary atherosclerosis. Will the hypothesis ever really pan out? J. Am. Coll. Cardiol. 58, 2007-2009. doi: 10.1016/j.jacc.2011.08.015
34. Muhlestein, J. B., Anderson, J. L., Hammond, E. H., Zhao, L., Trehan, S., Schwobe, E. P., et al. (1998). Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 97, 633-636. doi: 10.1161/01.CIR.97.7.633
35. Mukhopadhyay, S., Miller, R. D., Sullivan, E. D., Theodoropoulos, C., Mathews, S. A., Timms, P., et al. (2006). Protein expression profiles of Chlamydia pneumoniae in models of persistence versus those of heat shock stress response. Infect. Immun. 74, 3853-3863. doi: 10.1128/IAI.02104-05
36. O'Connor, C. M., Dunne, M. W., Pfeffer, M. A., Muhlestein, J. B., Yao, L., Gupta, S., et al. (2003). Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA 290, 1459-1466. doi: 10.1001/jama.290.11.1459
37. Phillips Campbell, R., Kintner, J., Whittimore, J., and Schoborg, R. V. (2012). Chlamydia muridarum enters a viable but non-infectious state in amoxicillin-treated BALB/c mice. Microbes Infect. 14, 1177-1185. doi: 10.1016/j.micinf.2012.07.017
38. Ramirez, J. A. (1996). Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. The Chlamydia pneumoniae/Atherosclerosis Study Groupgroup. Ann. Intern. Med. 125, 979-982. doi: 10.7326/0003-4819-125-12-199612150-00008
39. Rosenfeld, M. E., and Campbell, L. A. (2011). Pathogens and atherosclerosis: update on the potential contribution of multiple infectious organisms to the pathogenesis of atherosclerosis. Thromb. Haemost. 106, 858-867. doi: 10.1160/TH11-06-0392
40. Rothstein, N. M., Quinn, T. C., Madico, G., Gaydos, C. A., and Lowenstein, C. J. (2001). Effect of azithromycin on murine arteriosclerosis exacerbated by Chlamydia pneumoniae. J. Infect. Dis. 183, 232-238. doi: 10.1086/317941
41. Taylor-Robinson, D., and Boman, J. (2005). The failure of antibiotics to prevent heart attacks. BMJ 331, 361-362. doi: 10.1136/bmj.331.7513.361
42. Wyrick, P. B., and Knight, S. T. (2004). Pre-exposure of infected human endometrial epithelial cells to penicillin in vitro renders Chlamydia trachomatis refractory to azithromycin. J. Antimicrob. Chemother. 54, 79-85. doi: 10.1093/jac/dkh283